Failure to provide informed consent 
Inability to complete 400 m walk within 15 minutes without sitting or interpersonal assistance, as an indicator of disablement and likely inability to fully engage in the exercise intervention 
Primary indication for ACE inhibitor use, i.e. Congestive Heart Failure, CAD, diabetes 
Known hypersensitivity to ACE inhibitors 
Resistant hypertension, defined as BP > 140/90, despite the use of three or more anti-hypertensive drugs 
Office or average home SBP > 180 mm Hg or DBP > 110 mm Hg (Average home BP in any seven day period during trial) 
Primary renal disease 
Serum creatinine >2.5 mg/dL in men, or >2.0 mg/dL in women 
Serum potassium >5.0 molar equivalent/L 
Urinary protein > 1 on dipstick 
Abnormal liver enzymes (Aspartate transaminase (AST), Alanine transaminase (ALT), or alkaline phosphatase > 2.5 times the upper limit of normal) 
Severe cardiac disease, including New York Heart Association Class III or IV congestive heart failure, clinically significant aortic stenosis, history of cardiac arrest, use of a cardiac defibrillator, or uncontrolled angina 
Acute myocardial infarction identified by ECG 
Lives in a nursing home (persons living in assisted or independent housing will not be excluded) 
Significant cognitive impairment, defined as a known diagnosis of dementia or a Mini-Mental State Examination exam score < 24 
Unable to communicate because of severe hearing loss or speech disorder 
Severe visual impairment, which would preclude completion of the assessments and/or intervention 
Other significant co-morbid disease that would prevent participation in exercise 
Planning to move out of the area during the study time frame 
Simultaneous participation in another intervention trial       
    

NCT01891513_exc_T2
Condition
Inability to complete 400 m walk within 15 minutes without sitting
NCT01891513_exc_T3
Condition
interpersonal assistance Inability to complete 400 m walk within 15 minutes without
NCT01891513_exc_T4
Drug
ACE inhibitor
NCT01891513_exc_T5
Condition
Primary indication for ACE inhibitor use
NCT01891513_exc_T6
Condition
Congestive Heart Failure
NCT01891513_exc_T7
Condition
CAD
NCT01891513_exc_T8
Condition
diabetes
NCT01891513_exc_T9
Scope
Congestive Heart Failure, CAD, diabetes
NCT01891513_exc_T10
Condition
hypersensitivity to ACE inhibitors
NCT01891513_exc_T11
Drug
ACE inhibitors
NCT01891513_exc_T12
Condition
hypertension
NCT01891513_exc_T13
Qualifier
Resistant
NCT01891513_exc_T14
Measurement
BP
NCT01891513_exc_T15
Value
> 140/90
NCT01891513_exc_T16
Qualifier
despite the use of three or more anti-hypertensive drugs
NCT01891513_exc_T17
Drug
anti-hypertensive drugs
NCT01891513_exc_T18
Multiplier
three or more
NCT01891513_exc_T19
Measurement
SBP
NCT01891513_exc_T20
Value
> 180 mm Hg
NCT01891513_exc_T21
Measurement
DBP
NCT01891513_exc_T22
Value
> 110 mm Hg
NCT01891513_exc_T23
Condition
Primary renal disease
NCT01891513_exc_T24
Measurement
Serum creatinine
NCT01891513_exc_T25
Value
>2.5 mg/dL
NCT01891513_exc_T26
Person
men
NCT01891513_exc_T27
Value
>2.0 mg/dL
NCT01891513_exc_T28
Person
women
NCT01891513_exc_T29
Scope
>2.5 mg/dL in men, or >2.0 mg/dL in women
NCT01891513_exc_T30
Measurement
Serum potassium
NCT01891513_exc_T31
Value
>5.0 molar equivalent/L
NCT01891513_exc_T32
Measurement
Urinary protein on dipstick
NCT01891513_exc_T33
Value
> 1
NCT01891513_exc_T34
Measurement
liver enzymes
NCT01891513_exc_T35
Measurement
Aspartate transaminase (AST)
NCT01891513_exc_T36
Measurement
Alanine transaminase (ALT)
NCT01891513_exc_T37
Measurement
alkaline phosphatase
NCT01891513_exc_T38
Value
> 2.5 times the upper limit of normal
NCT01891513_exc_T39
Scope
Aspartate transaminase (AST), Alanine transaminase (ALT), or alkaline phosphatase
NCT01891513_exc_T40
Value
Abnormal
NCT01891513_exc_T41
Scope
Abnormal liver enzymes
NCT01891513_exc_T42
Condition
cardiac disease
NCT01891513_exc_T43
Qualifier
Severe
NCT01891513_exc_T44
Measurement
New York Heart Association
NCT01891513_exc_T45
Value
Class III or IV
NCT01891513_exc_T46
Condition
congestive heart failure
NCT01891513_exc_T47
Qualifier
clinically significant
NCT01891513_exc_T48
Condition
aortic stenosis
NCT01891513_exc_T49
Observation
history
NCT01891513_exc_T50
Condition
cardiac arrest
NCT01891513_exc_T51
Device
cardiac defibrillator
NCT01891513_exc_T52
Condition
uncontrolled angina
NCT01891513_exc_T53
Qualifier
New York Heart Association Class III or IV
NCT01891513_exc_T54
Condition
Acute myocardial infarction
NCT01891513_exc_T55
Procedure
ECG
NCT01891513_exc_T56
Observation
Lives in a nursing home
NCT01891513_exc_T57
Condition
cognitive impairment
NCT01891513_exc_T58
Qualifier
Significant
NCT01891513_exc_T59
Condition
dementia
NCT01891513_exc_T60
Measurement
Mini-Mental State Examination
NCT01891513_exc_T61
Value
score < 24
NCT01891513_exc_T62
Condition
Unable to communicate
NCT01891513_exc_T63
Condition
severe hearing loss
NCT01891513_exc_T64
Condition
speech disorder
NCT01891513_exc_T65
Scope
severe hearing loss or speech disorder
NCT01891513_exc_T66
Condition
visual impairment
NCT01891513_exc_T67
Qualifier
Severe
NCT01891513_exc_T68
Condition
co-morbid disease
NCT01891513_exc_T69
Qualifier
significant
NCT01891513_exc_T70
Qualifier
that would prevent participation in exercise